Asthma, Allergic Recruiting Phase 2 Trials for Tregalizumab (DB13073)

Also known as: Asthma Atopic / Atopic Asthma / Allergic Asthma / Extrinsic asthma - atopy (& pollen) / Extrinsic asthma NOS (disorder) / Extrinsic asthma (disorder) / Allergic asthma (disorder) / Asthma extrinsic / Extrinsic asthma / Allergic atopic asthma [Ambiguous] / Asthma / Asthma: [extrinsic - atopic] or [allergic] or [pollen] or [childhood] or [with hay fever] / Extrinsic asthma [Ambiguous] (disorder) / Bronchial asthma / Other and unspecified asthma / Asthma, unspecified / Asthma bronchial / Asthma unspecified (disorder) / Asthmatic bronchitis NOS / Asthma: [NOS] or [attack] / Asthma NOS / (Asthma: [exercise induced] or [allergic NEC] or [NOS]) or (allergic bronchitis NEC) / Asthma (disorder) / Asthma NOS (disorder) / Asthmatic bronchitis (disorder) / Asthma (disorder) [Ambiguous] / Asthmatic / Br. asthma / Bronchitic asthma

IndicationStatusPhase
DBCOND0047182 (Asthma, Allergic)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04673591Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic PatientsTreatment